RBC Capital maintains AbbVie at Outperform, raises price target to $330 from $280

What happened

RBC Capital kept its Outperform rating on AbbVie and raised its price target to $330 from $280, a 17.9% increase. The target implies 11.9% upside from AbbVie’s October 30 closing price of $294.89.

Confirmed

Global impact / market context

The higher target signals that RBC sees more potential value in AbbVie shares than before, which may support investor interest. However, a price target is an analyst estimate, not a promised return, and the article gives no new company operating or financial results.

Analyst inference

The five most recent analyst notes cited over the past 30 days set targets from $280 to $338, with RBC’s new $330 target near the upper end. That spread shows analysts differ on AbbVie’s potential share value.

Confirmed

What to watch

1. Compare upcoming analyst targets with RBC’s $330 estimate and the cited $280–$338 range to see whether views on AbbVie’s potential value are converging or diverging. Analyst inference
2. Watch for company results or guidance in future supplied updates; this article reports no new operating figures that explain RBC’s higher target. Analyst inference
3. The stated 11.9% implied upside uses the October 30 close of $294.89; any later share price would change the comparison with RBC’s target. Confirmed

Evidence

• Original source link unavailable